Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors
The Phase 1 study of Figitumumab combined with Pegvisomant aimed to evaluate safety and tolerability in patients with advanced solid tumors. The trial was terminated due to recruitment challenges and business considerations, rather than safety concerns. This indicates potential market limitations for this combination therapy, as it may not have demonstrated sufficient efficacy or competitive advantage in a crowded oncology landscape. The combination targets IGF-1R, which is implicated in various cancers, but the competitive landscape includes other therapies targeting similar pathways. Further diligence is warranted to assess the commercial viability of pursuing this combination in future studies or alternative indications.
Indication: Colorectal Neoplasms
Modality: monoclonal antibody
Target: Insulin-like Growth Factor 1 Receptor (IGF-1R)
Sponsor: Pfizer
Source URL: ClinicalTrials.gov
Source updated: Dec 13, 2013
Ingested: Jun 16, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Insulin-like Growth Factor 1 Receptor (IGF-1R)
View original source fields
Condition raw: Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Sarcoma
Condition normalized: Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Sarcoma
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: Insulin-like Growth Factor 1 Receptor (IGF-1R)
Target normalized: Insulin-like Growth Factor 1 Receptor (IGF-1R)